Headlands Technologies LLC Acquires New Shares in uniQure (NASDAQ:QURE)

Headlands Technologies LLC bought a new position in uniQure (NASDAQ:QURE) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 18,450 shares of the biotechnology company’s stock, valued at approximately $326,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Franklin Resources Inc. purchased a new position in uniQure during the third quarter valued at approximately $7,360,000. Point72 Asset Management L.P. raised its holdings in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. FMR LLC lifted its position in uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares during the last quarter. Monaco Asset Management SAM bought a new stake in uniQure in the 4th quarter worth approximately $2,414,000. Finally, Raymond James Financial Inc. bought a new position in uniQure during the fourth quarter valued at approximately $1,951,000. 78.83% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the transaction, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. The trade was a 4.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 in the last quarter. 4.74% of the stock is owned by company insiders.

uniQure Price Performance

QURE stock opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The firm has a 50-day moving average of $13.25 and a 200 day moving average of $10.91. The company has a market cap of $484.53 million, a P/E ratio of -1.81 and a beta of 0.37.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on QURE. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. The Goldman Sachs Group increased their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. StockNews.com raised uniQure to a “sell” rating in a research note on Tuesday, March 11th. Finally, Leerink Partners lifted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.